MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. It operates stores in Telangana, Andhra Pradesh, Karnataka, Tamil Nadu, West Bengal, Maharashtra, Orissa, Madhya Pradesh, Chhattisgarh, Kerala, and Puducherry, as well as online platform. The company was incorporated in 2006 and is based in Hyderabad, India.
Revenue projections:
Revenue projections for MEDPLUS With MEDPLUS's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.
Financial Ratios:
currentRatio
0.00000
forwardPE
47.44249
debtToEquity
62.95500
earningsGrowth
2.35100
revenueGrowth
0.08300
grossMargins
0.23086
operatingMargins
0.04487
trailingEps
11.03000
forwardEps
15.12000
MEDPLUS's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that MEDPLUS is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Price projections:
Price projections for MEDPLUS Over time, price projections for MEDPLUS have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in MEDPLUS's ability to achieve strong financial results.
Recommendation changes over time:
Recommendations trend for MEDPLUS
Analysts' buy bias for MEDPLUS signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to MEDPLUS, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
This article analyzes the recently announced 5% remittance tax by the Trump...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.